Mostrar el registro sencillo del ítem
Progranulin in Musculoskeletal Inflammatory and Degenerative Disorders, Focus on Rheumatoid Arthritis, Lupus and Intervertebral Disc Disease: A Systematic Review
dc.contributor.author | González Rodríguez, María | |
dc.contributor.author | Ait Edjoudi, D. | |
dc.contributor.author | Cordero Barreal, Alfonso | |
dc.contributor.author | Ruiz Fernández, Clara | |
dc.contributor.author | Farrag, M. | |
dc.contributor.author | González-Rodríguez, B. | |
dc.contributor.author | Lago Paz, Francisca | |
dc.contributor.author | Capuozzo, M. | |
dc.contributor.author | González-Gay Mantecón, Miguel Ángel | |
dc.contributor.author | Mera Varela, Antonio | |
dc.contributor.author | Pino Mínguez, Jesús | |
dc.contributor.author | Farrag, Y. | |
dc.contributor.author | Gualillo, Oreste | |
dc.date.accessioned | 2025-08-26T11:00:06Z | |
dc.date.available | 2025-08-26T11:00:06Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | González-Rodríguez M, Ait Edjoudi D, Cordero Barreal A, Ruiz-Fernández C, Farrag M, González-Rodríguez B, et al. Progranulin in Musculoskeletal Inflammatory and Degenerative Disorders, Focus on Rheumatoid Arthritis, Lupus and Intervertebral Disc Disease: A Systematic Review. Pharmaceuticals. 2022;15(12). | |
dc.identifier.issn | 1424-8247 | |
dc.identifier.other | https://portalcientifico.sergas.gal/documentos/63b996e14386723d2da37900 | * |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/20781 | |
dc.description.abstract | Progranulin (PGRN) is a glycoprotein formed by 593 amino acids encoded by the GRN gene. It has an important role in immunity and inflammatory response, as well as in tissue recovery. Its role in musculoskeletal inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and intervertebral disc degeneration disease (IVDD), is, nowadays, an important target to investigate. The objective of this review is to systematically sum up all the recent findings concerning PGRN as a target in the development and resolution of the inflammatory diseases. PubMed was examined with the terms combinations (Progranulin) AND (Lupus Erythematosus, Systemic), (Progranulin) AND (Arthritis, Rheumatoid), and (Progranulin) AND (Intervertebral Disc Degeneration). PubMed was examined with the terms combinations (Atsttrin) AND (Lupus Erythematosus, Systemic), (Atsttrin) AND (Arthritis, Rheumatoid), and (Atsttrin) AND (Intervertebral Disc Degeneration). Moreover, research through Web of Science was performed searching the same items. The inclusion criteria were: studies whose main topic were progranulin, or atsttrin, with emphasis on the three selected diseases. On the other hand, the exclusion criteria were studies that only focused on diseases not related to RA, lupus or IVDD, in addition to the previous published literature reviews. Since few results were obtained, we did not filter by year. The records assessed for eligibility were 23, including all the studies with the information in state of art of progranulin and its capability to be a potential target or treatment for each one of the selected diseases. As these results are descriptive and not clinical trials, we did not perform risk of bias methods. Within these results, many studies have shown an anti-inflammatory activity of PGRN in RA. PGRN levels in serum and synovial fluids in RA patients were reported higher than controls. On the other hand, serum levels were directly correlated with SLE disease activity index, suggesting an important role of PGRN as a player in the progression of inflammatory diseases and a therapeutical approach for the recovery. This review has some limitations due to the small number of studies in this regard; therefore, we highlight the importance and the necessity of further investigation. No external funding was implicated in this systematical review. | en |
dc.description.sponsorship | O.G. and F.L. are Staff Personnel (I3SNS Stable Researcher) of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff contract (ISCIII)/SERGAS). O.G. and M.A.G.G. are members of RICORS Programme, RD21/0002/0025 via ISCIII and FEDER. F.L. is a member of Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV). The work of O.G. and J.P. (PI20/00902), and F.L. (PI21/01145 and CB16/11/00226) is funded by ISCIII and FEDER. O.G. is a beneficiary of a project funded by the Research Executive Agency of the European Union in the framework of MSCA- RISE Action of the H2020 Programme (project number 734899). O.G. is the beneficiary of a grant funded by Xunta de Galicia, Conselleria de Educacion, Universidade e Formacion Profesional and Conselleria de Economia, Emprego e Industria (GAIN) (GPC IN607B2022/03). M.G-R. is a recipient of predoctoral contract funded by Xunta de Galicia (IN606A-2020/010). ISCIII and FEDER funded through a predoctoral research scholar to C.R-F. (Exp.18/00188). A.C.B. is a recipient of a predoctoral contract funded by Secretaria de Estado de Universidades, Investigacion, Desarrollo e Innovacion, Ministerio de Universidades (FPU2018-04165). Y.F is a 'Sara Borrell' researcher funded by ISCIII and FEDER [CD21/00042]. The funders were not involved in study design, data collection and analysis, decision to publish or manuscript preparation. | en |
dc.language.iso | eng | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Progranulin in Musculoskeletal Inflammatory and Degenerative Disorders, Focus on Rheumatoid Arthritis, Lupus and Intervertebral Disc Disease: A Systematic Review | * |
dc.type | Review | en |
dc.authorsophos | González-Rodríguez, O. M. | |
dc.authorsophos | Ait Edjoudi, D. | |
dc.authorsophos | Cordero Barreal, A. | |
dc.authorsophos | Ruiz-Fernández, C. | |
dc.authorsophos | Farrag, M. | |
dc.authorsophos | González-Rodríguez, B. | |
dc.authorsophos | Lago, F. | |
dc.authorsophos | Capuozzo, M. | |
dc.authorsophos | Gonzalez-Gay, M. A. | |
dc.authorsophos | Mera Varela, A. | |
dc.authorsophos | Pino, J. | |
dc.authorsophos | Farrag, Y. | |
dc.authorsophos | Gualillo | |
dc.identifier.doi | 10.3390/ph15121544 | |
dc.identifier.sophos | 63b996e14386723d2da37900 | |
dc.issue.number | 12 | |
dc.journal.title | Pharmaceuticals | * |
dc.relation.projectID | ISCIII [RD21/0002/0025, PI20/00902, PI21/01145, CB16/11/00226]; FEDER [Exp.18/00188, CD21/00042]; Research Executive Agency of the European Union in the framework of MSCA- RISE Action of the H2020 Programme [734899]; Xunta de Galicia, Conselleria de Educacion, Universidade e Formacion Profesional and Conselleria de Economia, Emprego e Industria (GAIN) [GPC IN607B2022/03]; Xunta de Galicia [IN606A-2020/010]; Secretaria de Estado de Universidades, Investigacion, Desarrollo e Innovacion, Ministerio de Universidades [FPU2018-04165] | |
dc.relation.publisherversion | https://www.mdpi.com/1424-8247/15/12/1544/pdf?version=1671009872;https://mdpi-res.com/d_attachment/pharmaceuticals/pharmaceuticals-15-01544/article_deploy/pharmaceuticals-15-01544-v2.pdf?version=1671009872 | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | AS Santiago | es |
dc.subject.keyword | IDIS | es |
dc.subject.keyword | CHUS | es |
dc.typefides | Artículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis) | es |
dc.typesophos | Artículo de Revisión | es |
dc.volume.number | 15 |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
